ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 ANS Winter Conference & Expo
November 15–18, 2026
Phoenix, AZ|Arizona Grand Resort & Spa
Latest Magazine Issues
Aug 2026
Jan 2026
2026
Latest Journal Issues
Nuclear Science and Engineering
October 2026
Nuclear Technology
September 2026
Fusion Science and Technology
August 2026
Latest News
LLNL, Ampera partner to develop thorium-based TRISO fuel
Lawrence Livermore National Laboratory has formed a strategic partnership with Ampera to develop the company’s nuclear fuel concept through a project named THUNDER, for Thorium Unimodal Droplet Ejection for Reactors.
The focus of THUNDER is fabricating TRISO made with kernels of thorium rather than the usual uranium. LLNL and Ampera will evaluate and optimize liquid metal–jetting technology to produce highly uniform, spherical kernels of thorium-232 for later processing into TRISO fuel.
William A. Neuman, James L. Jones
Nuclear Technology | Volume 92 | Number 1 | October 1990 | Pages 77-92
Technical Paper | Development of Nuclear Gas Cleaning and Filtering Techniques / Fission Reactor | doi.org/10.13182/NT90-A34488
Articles are hosted by Taylor and Francis Online.
A conceptual design of a passively safe reactor facility for boron neutron capture therapy is presented. The facility configuration and its neutronic, thermalhydraulic, and safety issues are addressed in order to demonstrate the deployability of reactor technology for routine patient treatments and advanced research and dosimetry. The reactor has a power level of <10 MW(thermal) and is based on low-enriched UZrH fuel. The reactor facility generates a clean epithermal neutron beam capable of treating deep-seated brain tumors (∼70 mm) in <10 min. The incident fast neutron and gamma-ray contaminants in the beam are 1.8 and 0.4 Gy, respectively, for a 20-Gy therapeutic dose to a deep-seated tumor. With an expected operation schedule of ∼2000 treatment periods per year, the reactor core lifetime is equal to the 30-yr facility lifetime and no refueling is necessary. Five beam ports are available for simultaneous patient treatments allowing between 2000 and 10000 treatments per year with expansion capabilities of at least threefold for 24 h/day operation. The cost per patient treatment is small, about $1000, making the therapy very affordable. The reactor system design includes several passive safety features that allow the reactor to respond in a safe and benign manner in the event of off-normal transients. The response for various instantaneous reactivity insertions is assessed. Results show the reactor can passively respond to a reactivity insertion of 2 $ such that the maximum temperature limits of the fuel are not exceeded.